These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 28934557

  • 1. A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes.
    Gallwitz B.
    Expert Opin Drug Saf; 2017 Dec; 16(12):1399-1405. PubMed ID: 28934557
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.
    Rizos CV, Filippatos TD, Elisaf MS.
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):117-125. PubMed ID: 29241374
    [Abstract] [Full Text] [Related]

  • 3. Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
    Kim ES, Deeks ED.
    Drugs; 2015 Sep; 75(13):1547-57. PubMed ID: 26323340
    [Abstract] [Full Text] [Related]

  • 4. Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes.
    Tan X, Hu J.
    Ann Endocrinol (Paris); 2016 Oct; 77(5):557-562. PubMed ID: 27062036
    [Abstract] [Full Text] [Related]

  • 5. Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus.
    Jain RK.
    Expert Opin Pharmacother; 2017 Apr; 18(6):545-549. PubMed ID: 28375658
    [Abstract] [Full Text] [Related]

  • 6. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.
    Lingvay I, Beetz N, Sennewald R, Schuler-Metz A, Bertulis J, Loley C, Lang B, Lippert C, Lee J, Manning LS, Terada D.
    Postgrad Med; 2020 May; 132(4):337-345. PubMed ID: 32366156
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Relative bioavailability of an empagliflozin 25-mg/linagliptin 5-mg fixed-dose combination tablet
.
    Glund S, Mattheus M, Runge F, Rose P, Friedrich C.
    Int J Clin Pharmacol Ther; 2017 Apr; 55(4):355-367. PubMed ID: 28290274
    [Abstract] [Full Text] [Related]

  • 10. The safety of empagliflozin plus metformin for the treatment of type 2 diabetes.
    Scheen AJ.
    Expert Opin Drug Saf; 2018 Aug; 17(8):837-848. PubMed ID: 30068236
    [Abstract] [Full Text] [Related]

  • 11. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
    Triplitt C, Solis-Herrera C, Cersosimo E, Abdul-Ghani M, Defronzo RA.
    Expert Opin Pharmacother; 2015 Aug; 16(18):2819-33. PubMed ID: 26583910
    [Abstract] [Full Text] [Related]

  • 12. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
    Friedrich C, Metzmann K, Rose P, Mattheus M, Pinnetti S, Woerle HJ.
    Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
    [Abstract] [Full Text] [Related]

  • 13. Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials.
    Watada H, Yamauchi T, Yamamoto F, Taniguchi A, Yarush L, Heilmann C, Yasui A.
    Expert Opin Drug Saf; 2020 Sep; 19(9):1193-1202. PubMed ID: 32552153
    [Abstract] [Full Text] [Related]

  • 14. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
    DeFronzo RA, Lewin A, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC.
    Diabetes Care; 2015 Mar; 38(3):384-93. PubMed ID: 25583754
    [Abstract] [Full Text] [Related]

  • 15. Glyxambi--a new combination for type 2 diabetes.
    Med Lett Drugs Ther; 2015 Apr 27; 57(1467):65-6. PubMed ID: 25897551
    [No Abstract] [Full Text] [Related]

  • 16. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.
    Scheen AJ.
    Expert Opin Drug Metab Toxicol; 2016 Dec 27; 12(12):1407-1417. PubMed ID: 27435042
    [Abstract] [Full Text] [Related]

  • 17. An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors.
    Lamos EM, Hedrington M, Davis SN.
    Expert Opin Drug Saf; 2019 Aug 27; 18(8):691-701. PubMed ID: 31150300
    [Abstract] [Full Text] [Related]

  • 18. Single-pill Combination of Empagliflozin and Linagliptin in Real World Indian Type 2 Diabetes Patient (GRID).
    Kovil R, Saboo B, Shah K, Padhye D, Chudasama D, Raj V, Shaikh N.
    J Assoc Physicians India; 2020 Oct 27; 68(10):53-55. PubMed ID: 32978926
    [Abstract] [Full Text] [Related]

  • 19. Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Mar 26; 60(1543):55-56. PubMed ID: 29635266
    [No Abstract] [Full Text] [Related]

  • 20. Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials.
    DeFronzo RA, Lee C, Kohler S.
    Adv Ther; 2018 Jul 26; 35(7):1009-1022. PubMed ID: 29949041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.